AIDS - Related Kaposi's Sarcoma - Pipeline Review, H1 2014, New Report Launched

'AIDS - Related Kaposi's Sarcoma - Pipeline Review, H1 2014', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for AIDS - Related Kaposi's Sarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for AIDS - Related Kaposi's Sarcoma. AIDS - Related Kaposi's Sarcoma - Pipeline Review, Half Year is built using data and information sourced from Publisher’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Publisher’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• A snapshot of the global therapeutic scenario for AIDS - Related Kaposi's Sarcoma.
• A review of the AIDS - Related Kaposi's Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the AIDS - Related Kaposi's Sarcoma pipeline on the basis of route of administration and molecule type.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for AIDS - Related Kaposi's Sarcoma.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding AIDS - Related Kaposi's Sarcoma pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Spanning over 53 pages, “AIDS - Related Kaposi's Sarcoma - Pipeline Review, H1 2014” report covered 5 companies - Aphios Corporation, CytRx Corporation, Cannabis Science, Inc., Xiamen Amoytop Biotech Co., Ltd., Biogenomics.

Inquiry for more information visit:  http://www.marketresearchreports.com/global-markets-direct/aids-related-kaposis-sarcoma-pipeline-review-h1-2014

Find All Diseases Reports at:- http://www.marketresearchreports.com/diseases  

For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter